Health Canada
www.hc-sc.gc.ca
Common menu bar links
H1N1 and Seasonal Influenza (Flu)
Consumers/patients and health professionals can find important adverse reaction information below related to antiviral drugs and vaccines used for the prevention and treatment of H1N1 and seasonal influenza (flu).
Information for Consumers and Patients
Report an Adverse Reaction to an Antiviral Drug or Vaccine
- Report an adverse reaction to an antiviral drug, a vaccine or other health products
- Guidelines for Reporting Suspected Adverse Reactions to Antiviral Drugs During an Influenza Pandemic
New Safety Information for the General Public Related to Antivirals and the H1N1 and Seasonal Influenza Vaccines (Since April 2010)
- New Expiry Date for Unused Adjuvanted H1N1 Vaccine (Arepanrix) [2010-04-09]
- Misconceptions about Vaccine Safety [2009-11-26]
- Consumers Warned Against Buying Fraudulent H1N1 Flu Virus Products Online [2009-11-05]
- Potential Medication Errors with Liquid Tamiflu (antiviral medication) [2009-09-28]
All Other New Safety Information for Consumers and Patients – Advisories, Warnings and Recalls
Stay Informed – MedEffect Canada
Information for Health Professionals
Report an Adverse Reaction to an Antiviral Drug or a Vaccine
- Report an adverse reaction to an antiviral drug, a vaccine or other health products
- Guidelines for Reporting Suspected Adverse Reactions to Antiviral Drugs During an Influenza Pandemic
New Safety Information for Health Professionals Related to Antivirals and the H1N1 and Seasonal Influenza Vaccines (Since April 2010)
- New Expiry Date for Unused Adjuvanted H1N1 Vaccine (Arepanrix) [2010-04-09]
- Authorization for Sale and Post-Market Activities for Arepanrix H1N1 Vaccine - GlaxoSmithKline Inc.
[2009-11-16] - Association of Relenza (zanamivir) dry powder for inhalation with fatal outcome when administered by nebulization instead of inhalation - GlaxoSmithKline [2009-11-05]
- Important Tamiflu Information for Health Professionals [2009-10-23]
- Important Information About the Risk of Dosing Error for Tamiflu (oseltamivir phosphate) Powder for Oral Suspension (12 mg/mL) - Hoffmann-La Roche Limited [2009-10-15]
All Other New Safety Information for Health Professionals – Advisories, Warnings and Recalls
Stay Informed – MedEffect Canada
Related Links
Health Canada
Public Health Agency of Canada
